A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
Latest Information Update: 18 Mar 2025
At a glance
- Drugs MDI 2517 (Primary)
- Indications Interstitial lung diseases; Systemic scleroderma
- Focus Adverse reactions; First in man
- Sponsors MDI Therapeutics
- 14 Mar 2025 Status changed from recruiting to completed.
- 27 Sep 2024 Planned number of patients changed from 48 to 64.
- 27 Sep 2024 Planned End Date changed from 1 Sep 2024 to 1 Feb 2025.